View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 7, 2018

Mereo BioPharma to merge with OncoMed Pharmaceuticals

British pharmaceutical company Mereo BioPharma Group has announced a proposal to merge with US-based drugmaker OncoMed Pharmaceuticals.

British pharmaceutical company Mereo BioPharma Group has announced a proposal to merge with US-based drugmaker OncoMed Pharmaceuticals.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

The integrated business will feature a portfolio of seven assets, including three of Mereo’s Phase II candidates for osteogenesis imperfecta and alpha-1 antitrypsin deficiency.

Mereo BioPharma noted that after the completion of the merger, its focus will be on orphan diseases.

The company also expects potential alliances between its BCT-197 and BGS-649 programmes and OncoMed’s navicixizumab programme.

In addition, the combined entity will retain its ongoing partnership with Celgene, with an option to licence OncoMed’s etigilimab (anti-TIGIT) programme.

The business is also expected to benefit from combined skills and expertise, established operational base in the US and expanded board of directors.

Mereo BioPharma CEO Dr Denise Scots-Knight said: “The transaction allows us to broaden our asset base, including strengthening our cash position to enable us to progress beyond our key clinical milestones.

“We believe that our plan to initiate a US ADR programme on NASDAQ, in addition to the continued listing of our ordinary shares on AIM, will facilitate a deep engagement with the broadest range of appropriate investors.”

“The transaction allows us to broaden our asset base, including strengthening our cash position to enable us to progress beyond our key clinical milestones.”

OncoMed is undertaking a restructuring that will see significant reduction in existing workforce.

OncoMed Pharmaceuticals president and CEO Dr John Lewicki said: “We believe this is a value-enhancing transaction for both companies, forming an organisation with a much expanded pipeline of diversified assets and strengthened capabilities and resources.

“We look forward to working closely with the Mereo team to finalise the transaction and assist in assimilation of the combined assets.”

Subject to customary closing conditions, the transaction is expected to close in the first half of next year. After the closing, OncoMed is set to operate as a 100% owned subsidiary of Mereo Biopharma.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology